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Review article 
 
Treatment strategies in acute myeloid leukemia 
 
HAN Li-na, ZHOU Jin, Jan Jacob Schuringa and Edo Vellenga 
 
Keywords: acute myeloid leukemia; leukemic stem cell; treatment; novel agents 
 
Objective  To summarize the risk stratification and current treatment strategies for acute myeloid leukemia (AML) and 
discuss the role of emerging novel agents that might be applied in future clinical trials. 
Data sources  The data in this article were collected from PubMed database with relevant English articles published 
from 1991 to 2009.  
Study selection  Articles regarding the risk stratification and therapeutic options of AML, as well as the characteristics 
of leukemic stem cells were selected. 
Results  AML is a heterogeneous disease with variable clinical outcome dependent on several prognostic factors, 
including age, cytogenetics and molecular markers. The advances in the understanding of AML pathogenesis and 
development will generate potential novel agents that might improve the treatment results of standard chemotherapy.  
Conclusion  Deeper insight into the multiple transforming events of AML may aid us in designing combinations of small 
molecule inhibitors based on the individual patient characteristics. 
Chin Med J 2011;124(9):1409-1421 
 
cute myeloid leukemia (AML) is characterized by an 
accumulation of primitive hematopoietic cells in the 
bone marrow compartment due to a differentiation defect 
in stem/progenitor cells, resulting in disruption of normal 
hematopoiesis. Currently AMLs are categorized 
according to the World Health Organization (WHO) 
classification that is especially based on chromosomal 
abnormalities. Four subgroups of AMLs are classified. 
The first group is characterized by recurrent genetic 
abnormalities of prognostic significance. The second 
group is AML with myelodysplasia-related changes and 
the third group is therapy-related myeloid neoplasms. For 
the AML not otherwise specified (NOS), the definition is 
based on morphological and cytochemical and immuno- 





Several clinical studies have shown that the treatment of 
AML is dependent on several prognostic factors, 
including age, cytogenetics, mutational status and 
intensity of post-remission therapy. Cytogenetic features 
are the most well-defined prognostic factors, dividing 
patients into 3 main groups categorized as favorable, 
intermediate, and unfavorable risk groups.1,2 The 
unfavorable risk group can be further divided based on 
the presence of a monosomy karyotype (Figure 1).3 The 
5-year overall survival (OS) is approximately 55%, 40% 
and 10% in the favorable, intermediate, and unfavorable 
risk groups, respectively. The age of the patients is tightly 
correlated with the cytogenetic features.4 The percentage 
of favorable cytogenetics drops from 20% to 7% with 
increasing age, while the percentage of patients in the 
unfavorable risk group increases from around 20% to 
50%.1,2,4-6 The relative high percentage of patients with 
high-risk features implies that the treatment outcome of 
elderly AML patients is poor.  
 
Although cytogenetic aberrations provide valuable 
information for AML diagnosis and prognosis, a 
proportion of AML patients within the same risk group 
show heterogeneous responses to treatment. Core binding 
factor (CBF) AML is cytogenetically defined by the 
presence of chromosomal translocation t(8;21) or inv(16), 
presenting with favorable clinical outcomes.7 Mutations 
in KIT in this subtype of AML conferred to a more 
unfavorable prognosis.8,9 Cytogenetically normal AMLs 
(CN AMLs) were identified in around 50% of the patients, 
representing as a large heterogeneous subgroup within the 
intermediate-risk group.1,2,10,11 Falini et al12 have recently 
shown that the group of patients can be further 
sub-divided based on the nucleophosmin (NPM) gene 
mutation. Patients with a NPM mutation without 
Fms-related tyrosine kinase 3 gene-internal tandem 
duplications (FLT3-ITDs) have a favorable prognosis that 
is comparable to patients categorized into the favorable 
risk group. CN AML patients with CCAAT/enhancer 
binding protein α (CEBPA) gene mutations also showed 
better OS,11 whereby some studies suggested that the 
favorable role of CEBPA mutations were mostly 
dependent on the absence of FLT3-ITD in CN AMLs.13  
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AML with recurrent genetic abnormalities   




AML with inv (16) (p13.1q22) or t (16;16) (p13.1q22) CBFB-MYH11 5–8 
APL with t(15;17) (q22;q12) PML-RARA 5–8 
AML with t(9;11) (p22;q23) MLLT3-MLL 2 
AML with t(6;9) (p23;q34) DEK-NUP214 1–2 
AML with inv (3) (q21;q26.2) or t(3;3) (q21;q26.2) RPN1-EVI1 1–2 
AML (megakaryoblastic) with t(1;22) (p13;q13) RBM15-MKL1 <1 
Provisional entity: AML with mutated NPM – 27–35 
Provisional entity: AML with mutated CEBPA – 6–15 
AML with myelodysplasia-related changes – 24–35 
Therapy-related myeloid neoplasms – 10–20 
AML, not otherwise specified (NOS) FAB  
AML with minimal differentiation (M0)  <5 
AML without maturation (M1)  5–10 
AML with maturation (M2)  10 
Acute myelomonocytic leukemia (M4)  5–10 
Acute monoblastic/monocytic leukemia (M5)  <5 
Acute erythroid leukemias (M6)  <5 
Pure erythroid leukemia  – 
Erythroleukemia, erythroid/myeloid  – 
Acute megakaryoblastic leukemia (M7)  <5 
Acute basophilic leukemia  <1 
Acute panmyelosis with myelofibrosis  Rare 
Myeloid sarcoma  – 
Myeloid proliferation related to down syndrome  – 
Transient abnormal myelopoiesis   
Myeloid leukemia associated with down syndrome   




Figure 1. Cytogenetic and molecular classifications. CK: 
complex karyotype. MK: monosomy karyotype. abn: abnormal. 
FLT3-ITD: FLT3-internal tandem duplications. mut: mutant. 
 
The AMLs with NPM mutant (mut) and wild type (wt) 
FLT3 can be further divided into subgroups based on the 
expression level of the erythroblastosis virus E26 
oncogene homologue (ERG) gene. High level of ERG 
expression correlates with shorter event-free survival 
(EFS).14 In young patients with CN AML, low inhibitors 
of differentiation (ID1) expression levels predicted better 
disease-free survival (DFS) than those with high ID1 
levels, with DFS even more improved in patients with 
NPMmut/FLT3-ITD negative.15 In the study by the cancer 
and leukemia group B (CLGB), WT1 mutation was also 
an independent adverse prognostic factor in CN AML.16 
However in the study by the German-Austrian AML 
study group, the negative impact of WT1 mutation was 
dependent on the presence of FLT3-ITDs in CN AML.17 
Other genetic alterations including brain and acute 
leukemia, cytoplasmic (BAALC), EVI1 and Meningioma 
1 (MN1) are also implicated in AML prognosis profiles, 
as negative indicators for OS.18-20 Those molecular 
features on prognosis are summarized in Figure 1. In the 
future, high-throughput gene expression profiling will 
allow a genome-wide identification of subgroups within 
CN AML.21-23 Recently, microRNA signature was also 
indicated in prognostically specific AML subgroups, 
associating with EFS.24    
 
Furthermore, fusion transcripts such as RUNX1- 
RUNX1T1 and CBFB-MYH11, as well as biomarkers, 
e.g. WT1, can be applied to monitor the minimal residual 
disease (MRD) and evaluate treatment response in 
AML.25 Using MRD studies, risk-based therapies for 
AML can be designed to minimize toxicity and improve 
cure rates.  
 
CURRENT TREATMENT STRATEGIES 
 
Treatment for AML other than acute promyelocytic 
leukemia (APL) 
Since APL is a unique subset of AML, with different 
treatment strategies and prognosis, it will be discussed 
separately. In this part, we focus on the treatment for 
AML other than APL.  
 
Induction therapy 
The 3+7 combination of the anthracycline daunorubicin 
(45 mg/m2 or 60 mg/m2 intravenously for 3 days) and 
cytarabine (Ara-C, 200 mg/m2 continuously intravenous 
infusion for 7 days) has been the standard initial 
treatment for AML for 3 decades.26 Approximately 50% 
to 75% of adults with AML achieve complete remission 
(CR) with this standard induction regimen.27,28 Attempts 
to improve CR rate by escalating the doses of cytarabine, 
substituting alternative anthracyclines idarubicin, addition 
of other cytotoxic agents, and others,11,29-32 have failed to 
show a significant survival advantage over the standard 
regimen, even though some approaches might improve 
EFS in certain subgroups. This treatment schedule was 
applied mostly for patients less than 60 years. Patients up 
to 60 years were treated with less intensive regimens. But 
a recent study has indicated that the treatment outcome of 
patients between 60 and 65 years can be improved by a 
more intense regimen especially for those in favorable 
risk group.33 Remission induction chemotherapy has been 
proven to be important in elderly AML patients for 
improving clinical outcomes and is superior to 
reduced-dose chemotherapy and supportive treatment.34,35 
Higher CR rates, lower early death rates and longer 
survival were achieved with intensive therapy compared 
with palliative therapy only. The clinical outcome 
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remains dismal in those patients with less tolerance to 
intensive chemotherapy, more preexisting comorbidities, 
and frequently unfavorable cytogenetics.4  
 
Consolidation therapy 
Consolidation treatment strategies have been applied in 
AML patients with CR to eliminate MRD, improve 
survival and increase cure rates. The treatment 
traditionally includes intensive consolidation 
chemotherapy, autologous stem cell transplantation 
(ASCT) or allogeneic stem cell transplantation (alloSCT) 
or combinations and low-dose maintenance therapy in the 
elderly patient group. Age and cytogenetic risk 
classification of the patients are important clinical 
parameters to determine the intensity of the consolidation 
therapy.  
 
Variable chemotherapy regimens have been applied; also 
the numbers of courses vary between the different study 
groups.6,11,30 In general, 1–3 courses are applied after 
obtaining CR. The high-dose Ara-C (HiDAC) has been 
studied as standard consolidation chemotherapy 
especially in the USA.36 The benefit was restricted to 
patients in favorable and intermediate risk groups, but not 
to patients in the unfavorable risk group.37,38 Elderly 
patients do not benefit from HiDAC, due to increased 
toxicity.  
 
Hematopoietic stem cell (HSC) transplantation is 
performed with collected HSCs harvested from either the 
patient (autologous), or a human leukocyte antigen 
(HLA)-matched donor (allogeneic). A number of study 
groups have the policy that patients belonging to the 
favorable risk group should not be exposed to 
transplantation in view of the favorable prognosis.39-41 
ASCT is typically evaluated in patients belonging to the 
intermediate risk group in first remission (CR1), who do 
not have an available HLA-matched related donor. Some 
large clinical trials showed improvement in EFS, but not 
OS.42,43 In a recent clinical trial, no significant difference 
in OS was observed between chemotherapy and ASCT in 
young adults with CN AML.11 Considering the higher 
mortality (<6%) of ASCT compared with consolidation 
chemotherapy, and improved efficacy of HiDAC, the 
advantage of ASCT is compromised compared to 
standard consolidation chemotherapy in this subgroup of 
patients.44,45  
 
AlloSCT is superior to ASCT for the presence of the 
immunological reaction referred to as graft-versus- 
leukemia (GVL) effect, in which the donated allogeneic 
cells recognize the recipients’ leukemic cells as foreign, 
resulting in a better EFS. But it is associated with a higher 
risk of treatment-related mortality (10%–25%), which 
also dependent on the applied conditioning 
regimens.11,27,28 The recommendation of allogeneic 
transplantation must be based on the individual clinical 
characteristics, including age, risk stratification, type of 
donor match and prognosis. Significantly longer EFS and 
OS have been revealed in a cohort of younger AML 
patients with normal karyotype.11 Reasonably, patients 
with unfavorable cytogenetics and some patients with 
intermediate cytogenetics, except for those who are 
NPMmut/FLT3-ITD negative, are candidates for 
alloSCT.28 A recent systematic review and meta-analysis 
demonstrated that alloSCT significantly improved EFS 
and OS in patients with intermediate and unfavorable risk, 
but not those with favorable risk, as compared with 
non-alloSCT.46  
 
Regarding the origin of the transplant, matched siblings 
should preferably be considered for alloSCT. Patients 
without matched siblings might receive a matched 
unrelated donor. The benefits were especially for patients 
≤40 years in the setting of myeloablative conditioning.47 
Recently, reduced-intensity conditioning regimens have 
been introduced which makes it possible that older 
patients can also be treated with an alloSCT.48 This 
provides the opportunity to transplant patients up to 
65–70 years. To enlarge the application of alloSCT, 
umbilical cord blood (UCB) can be an option for patients 
without a matched donor. The advantages of UCB include 
rapid availability, greater tolerance of HLA disparity and 
lower incidence of severe graft-versus-host disease, as 
well as safety to donors, easy harvesting and less risk of 
transmitting infection.49 But in adult patients, the major 
limitation is the low cell dose, which confers to the 
delayed engraftment, resulting in relatively higher 
infection rates. Double UCB transplantation can 
overcome the barrier of low cell dose and improve the 
hematological engraftment. As a summary, a schematic 
overview is shown for the therapeutic approaches in AML 
(Figure 2).  
 
Maintenance therapy 
Maintenance therapy is a standard care in APL, but has 
not convincingly been demonstrated to be effective in 
other subtypes of AMLs.28 Various maintenance regimens 
have been explored but no advantages with regard to EFS 
or OS have been observed.50,51  
 
Treatment in relapsed disease 
The majority of AML patients who gained first remission 
will relapse within 3 years of diagnosis.52 Treatment of 
relapsed AML is not satisfactory and chemotherapy alone 
is rarely curative. For those patients who can tolerate 
reinduction chemotherapy to obtain a second remission 
can proceed with ASCT or alloSCT. The most important 
factor to predict success for a second remission seems to 
be the duration of first CR. If the initial CR was more 
than 12 months, the possibility for a second CR could be 
40% to 50%, which dropped till 10% to 20% if the initial 
CR was less than 12 months.53-56 The 3+7 combination 
and high-dose cytarabine have been suggested as 
effective reinduction regimens.45,57 AlloSCT could be the 
preferable treatment for most relapsed patients, especially 
for those who achieve a second remission, due to its 
potent anti-leukemic effects. For patients who can not 
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Figure 2. Schematic overview of AML treatment strategies. 
DNR: daunorubicin. NPM: nucleophosmin. CEBPA: 
CCAAT/enhancer binding protein α. FLT3-ITD: FLT3-internal 
tandem duplications. AlloSCT: allogeneic transplantation. ASCT: 
autologous transplantation. MUD: matched unrelated donor. 
UCB: umbilical cord blood. HLA: human leucocyte antigen. 
RIC: reduced-intensity conditioning.  
 
tolerate a conventional conditioning regimen, 
nonmyeloablative and reduced-intensity allogeneic 
transplation seem effective.58 ASCT appears to be an 
option for AML in the second remission without 
availabledonors for allogeneic transplantation, with some 
possibilities of cure.59 A 10-year survival rate of 32% was 
reported in patients in second remission with favorable 
and intermediate cytogenetics.60 
 
Treatment for acute promyelocytic leukemia 
APL is a unique subset of AML characterized by the    
t(15;17) translocation which results in the PML-RAR 
fusion gene transcript.
 
                                    
Extramedullary infiltration (EMI) that includes tumor 
nodules (myeloid or granulocytic sarcoma), skin 
infiltration (leukemia cutis), meningeal infiltration, 
gingival infiltration, hepatosplenomegaly or central 
nervous system leukemia (CNSL), occurs in around 30% 
of patients with AML.
61,62 The main prognostic factors in 
APL are white blood cell (WBC) and platelet counts 
pretreatment. A predictive model based on WBC and 
platelet counts classified patients into 3 risk groups: 
low-risk group (WBC count ≤10×109/L and platelet count 
>40×109/L), intermediate-risk group (WBC count     
≤10×109/L and platelet count ≤40×109/L) and high-risk 
group (WBC count >10×109/L).63,64 Risk-adapted treatment 
protocols have been designed based on relevant 
characteristics. 
 
The current standard approach with all-trans retinoic acid 
(ATRA) plus anthracycline chemotherapy significantly 
improved the clinical outcome of newly diagnosed APL 
patients, with CR rate of approximately 90% and 5-year 
cumulative DFS of 84%.65-68 The addition of cytarabine 
in this regimen can benefit high-risk patients, but not low- 
and intermediate-risk groups.69 Alternatively, the benefit 
of ATRA/arsenic trioxide (ATO) combination therapy in 
newly diagnosed APL was demonstrated in a recent study 
from Chinese institutes. With a median follow-up of 70 
months, 94% of patients achieved CR, and 5-year EFS 
and OS were 89% and 92%.70 This combination therapy 
was also reported from the M.D. Anderson Cancer Center, 
with gemtuzumab ozogamicin (GO) added to high-risk 
patients.71 These analyses suggested that ATRA 
combining with ATO induction therapy without 
chemotherapeutic reagents could be safely and effectively 
applied in de novo APL and would require additional 
clinical studies. Recently the efficacy and safety of ATO 
as a single agent was demonstrated in newly diagnosed 
pediatric APL.72  
 
Consolidation therapy with at least 2 further cycles of 
anthracycline-based chemotherapy after induction allows 
the achievement of molecular remission of patients.73 The 
superiority of adding ATRA into consolidation was shown 
in GIMEMA and PETHEMA cooperative groups.74,75 The 
role of ATO in postinduction therapy was also identified 
with high antileukemic activity.76,77 Molecular assessment 
by real time polymerase chain reaction (RT-PCR) of 
promyelocytic leukemia-retinoic acid receptor alpha 
(PML-RARA) fusion gene was recommended at the end 
of consolidation chemotherapy to determine the relapse 
risk in APL patients.78,79 For patients achieving molecular 
remission after consolidation therapy, ATRA-based 
maintenance therapy for 2 years was recommended to 
eliminate the MRD and decrease the relapse rate.68,80 
 
Treatment for central nervous system leukemia 
(CNSL) in AML 
81,82 EMI has been reported to be 
more common in myelomonoblastic and monoblastic 
sybtypes of AML (FAB M4 and M5) and AML with 
favorable cytogenetics, e.g. t(8;21) and inv(16). The 
frequency of EMI in APL is reported to be between 
3%–8%.83 The prognostic significance of EMI is 
controversial. Some studies report that EMI confers a 
poor prognosis, particularly in pediatric AML patients or 
patients with t(8;21).81,84 With current treatment advances, 
extramedullary relapses outside the CNS have become 
exceedingly rare; however, CNS relapse still occurs in 
2%–4% of patients with AML.85,86 But due to the low 
frequency of CNS involvement in AML, controversy 
exists in prophylactic therapy for CNSL. CNS-directed 
treatment protocols of de novo AML patients include 
cranial irradiation, intrathecal treatment and systemic 
chemotherapy.85 Since contemporary treatment protocols 
include high-dose cytarabine or other drugs that penetrate 
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readily into the CNS, cranial irradiation is not necessary. 
For the intrathecal treatment, cytarabine, especially the 
liposomal cytarabine that can maintain a therapeutic level 
of cytarabine in cerebrospinal fluid, has been the 
preferred drug in AML by reducing the CNS relapse 
rates.87,88 It remains unclear for the effect of systemic 
chemotherapy on CNS prophylaxis in AML. And less is 
known about the best treatment for patients with isolated 
CNS relapse of AML. In summary, the strategy for CNS 
disease control still remains to be optimized. Further 
studies on large cohorts of AML patients need to be 
performed.  
 
CURRENT CHALLENGES OF AML TREATMENT 
 
Although many improvements have been achieved in the 
treatment of AML patients, clinical outcomes are still not 
satisfactory, which are strongly dependent on the risk 
group. Emerging studies consider that leukemic stem 
cells (LSCs) initiate and maintain AML, and their 
quiescent state contributes to resistance of the 
conventional chemotherapy. Recent studies have 
demonstrated that leukemic transformation is a multistep 
process.89 Multiple acquired genetic changes occurred to 
convert normal HSC to LSC which was characterized by 
enhanced self-renewal, increased proliferation, impaired 
differentiation and apoptosis, resulting in accumulation of 
immature AML blasts.90 Understanding AML 
pathogenesis and biological properties of LSCs will be 
helpful to develop LSC-targeted therapies, and finally 
cure the disease since so far no further improvement has 
been obtained by more dose-intensification of 
chemotherapy. The following section will focus on novel 
agents targeting the unique properties of LSCs in AML.  
 
Targeting LSC by unique membrane antigens 
Theoretically, the plasma membrane molecules 
preferentially expressed in subsets of AML LSCs, such as 
CD123 (IL-3Rα), CD33, C-type lectin-like moledule-1  
(CLL-1), CD96 and CD47,91-94 would be ideal LSC 
targets. A neutralizing antibody (7G3) targeting CD123 
impaired the homing and engraftment ability of AML 
LSCs in NOD/SCID mice and inhibited IL-3-induced 
intracellular signaling of AML CD34+CD38– cells in 
vitro.95 This antibody is most effective when the leukemic 
burden is low, suggesting it can be applicable during 
remission induction after chemotherapy. A humanized 
anti-CD33 mAb, GO (Mylotarg) was approved by the 
FDA for treatment of CD33+ AML in the first relapse in 
elderly patients, who were not tolerable for 
chemotherapy.96 In phase II clinical trials, about 30% of 
elderly patients in the first relapse can achieve CR by 
using GO monotherapy.97,98 However, CD33 is also 
expressed on normal HSCs, which may explain the 
prolonged cytopenia following treatment with GO in 
some AML cases.99 So far the most prominent effect of 
GO has been observed in patients with relapsed APL, 
which might be due to a homogeneous CD33 expression 
pattern with increased antigen density of CD33 in APL.100 
Preclinical studies have recently also shown that CD47 
might be therapeutic target for AML stem cells.101,102 It 
was observed that treatment with anti-CD47 antibody can 
enable phagocytosis of AML LSCs and inhibit in vivo 
engraftment, without affecting their normal counterparts.  
 
Molecular targeting of activated tyrosine kinases  
FLT3 inhibitors 
Approximately 30% of AML cases contain FLT3-ITDs, 
which is a strong negative prognostic factor in AML, 
especially in conjunction with NPM mutations. Various 
small molecule kinase inhibitors against FLT3 activation 
have been developed and evaluated in AML patients, 
including PKC-412 (midostaurin), CEP-701 (lestaurtinib), 
SU-11248 (sunitinib), MLN-518 (tandutinib), KW-2449, 
SU-5416 and sorafenib.103-109 In most of those clinical 
trials, FLT3 inhibitors were evaluated in relapsed or 
refractory AML patients. Generally, FLT3 inhibitors 
showed only modest clinical efficacy, with blasts 
reduction as the most dominant effect. But CR is rarely 
observed. Recent studies revealed the importance of 
unique and sustained inhibition of FLT3, and developed a 
new compound, AC220, a uniquely potent and selective 
FLT3 inhibitor with desirable safety and pharmacokinetic 
profile.110,111 A recent study demonstrated that the 
sensitivity towards FLT3 inhibitors was enhanced by a 
CXCR4 antagonist by abrogating the protective signals 
from stromal cells.112 It is likely that single use of FLT3 
inhibitors will be of limited value especially from the 
perspective that leukemic transformation depends on at 
least two transforming events.89 Therefore, the effects of 
FLT3 inhibitor should be considered in the setting of 
additional chemotherapy.  
 
KIT inhibitors 
KIT mutations occur in more than 50% of patients with 
CBF AML, particularly in FAB M2 subtype, associating 
with inferior clinical outcomes.113 Imatinib mesylate (IM) 
inhibits KIT kinase activity, but it is limited to wt KIT 
and juxtamembrane domain mutations.114 KIT activation 
loop mutations are frequently noticed in AML samples 
that are resistant to imatinib.115,116 Dasatinib was designed 
as a dual ABL-/SRC-family kinase inhibitor.117 It was 
demonstrated that dasatinib can inhibit the kinase activity 
of both wt and mut KIT isoforms, with differential 
potency against mutations involving codon 816 and 822, 
suggesting it may benefit AML patients with KIT 
activation loop mutations.118,119 A recent report showed 
dasatinib treatment together with chemotherapy can 
induce long-term hematologic and molecular remission in 
a patient with AML harboring KIT D816V mutation.120 A 
potent KIT inhibitor, APcK110 showed inhibitory effects 
on AML blast colony-forming cell proliferation without 
affecting normal bone marrow cells.121 Those inhibitors 
could provide therapeutic advantages in AML, and their 
efficacy needs to be verified in clinical trials.  
 
Farnesyl transferase inhibitors 
Farnesyl transferase inhibitors (FTIs) have been 
developed to block constitutive RAS activation which 
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requires farnesyl transferase for localization to the plasma 
membrane.122 Tipifarnib, one of the FTIs that has been 
applied in phase II clinical trials with CR rates of 4% in 
refractory or relapsed AML patients and 14% in 
unfavorable-risk elderly patients.123-125 Prolonged DFS in 
a subgroup of unfavorable-risk patients was observed 
when tipifarnib was applied as maintenance therapy in 
CR1.125 Meanwhile, despite the initial attempts of FTIs to 
target RAS mutations, no correlation between RAS 
mutations and response of FTIs can be demonstrated in 
clinical trials.126 Furthermore, NRAS and KRAS, the 
most dominant isoforms involved in AML, can be 
alternatively geranylgeranylated to escape functional 
inactivation by FTIs.122 In summary, RAS mutations 




Epigenetics is defined as heritable changes in gene 
expression that are not accompanied by alterations in 
primary DNA sequence.127 Epigenetic modifiers targeting 
DNA methylation and histone acetylation (histone 
deacetylase, HDAC) have been developed to release the 
gene repression in AML. Various HDAC inhibitors, 
including e.g. romidepsin, valproic acid, butyrate, 
MGCD0103, and hydroxamic acid, did not show 
satisfactory results as single agents.128-132 DNA 
methyltransferase (DNMT) inhibitor azacitidine 
significantly improved OS as compared to conventional 
care, especially in patients with AML and high-risk 
myelodysplastic syndromes (MDS) with chromosome 5 
and 7 abnormalities.133,134 Recently, the superiority of 
azacitidine was demonstrated in AML patients with low 
marrow blast count (20%–30%).135 Dual targeting of both 
HDAC and DNMT was hypothesized to be a rational 
approach to AML treatment.130 However, this concept 
was challenged in a recent study in which reversal of 
promoter methylation was observed in both clinical 
responders and non-responders.136  
 
Inducing apoptosis 
A relative insensitivity to apoptotic stimuli results in 
survival advantages of the leukemic cells. Nuclear 
factor-kappa B (NF-κB) is highly activated in AML 
leukemic cells but not in normal CD34+ cells, suggesting 
inhibition NF-κB might induce LSC-specific 
apoptosis.137,138 MG-132, an inhibitor of NF-κB, showed 
rapid induction of apoptosis exclusively in LSCs, but not 
in normal CD34+ cells.139 The role of BCL-2, a member 
of anti-apoptotic family, was also identified in AML 
pathogenesis. In vitro, down-regulation of antisense 
oligonucleotides increased sensitivity of AML cell lines 
to chemotherapy.140 The efficacy of BCL-2 antisense 
oligonucleotide (G3139) has been proven in phase I 
clinical trials combining with chemotherapy.141,142  
 
Release of LSCs from their microenvironment 
Both normal and leukemic stem cells reside in a bone 
marrow niche, a specialized microenvironment.143-145 
Jagged-Notch, Tie2-Angiopoietin-1 and CXCR4-SDF1/ 
CXCL12 axis, as well as RAC signal transduction 
pathways have been demonstrated to be important in 
regulating the interaction of stem cells with their 
niche.144,146 Homing to the microenvironment is 
important for sustaining LSC survival. CD44, a 
transmembrane glycoprotein mediating cell-cell and 
cell-extracellular matrix interactions, was identified as a 
key regulator of AML LSCs.147 Targeting CD44 with a 
monoclonal antibody (H90) eradicated AML LSCs by 
blocking the homing ability and altering the stem cell fate. 
In addition, in a mouse model of CML, BCR-ABL-positive 
LSCs are more heavily dependent on CD44 for homing 
and engraftment as compared to normal HSCs.148 Those 
studies indicated that CD44 blockade can be a 
LSC-specific approach in leukemia treatment. CXCR4 
was highly expressed in AML blasts, predicting shorter 
survival independently.149 AMD3100, a small molecule 
inhibitor acting as CXCR4 antagonist, inhibited the 
transmigration and colony formation of AML blasts.150 
Administration of AMD3100 enhanced mobilization of 
leukemic blasts, increased sensitivity of chemotherapy 
and improved OS in mouse model.151 In the past two 
decades, hematopoietic growth factors have been applied 
as priming agents to drive leukemic cells entry into cell 
cycle and increase susceptibility to chemotherapy.30,152-154 
Some studies showed that younger AML patients with 
intermediate-risk cytogenetics might benefit from G-CSF 
or GM-CSF priming.30,154 A recent study demonstrated 
that G-CSF-mediated stem cell mobilization was 
CXCR4-dependent.155 It suggested that release of the 
leukemic cells from their protective environment was 
involved in the mechanisms of growth factor priming. 
The usefulness of CXCR4 antagonists in combination of 
chemotherapy may be provided in future clinical trials in 
AML patients.  
 
Targeting ATP-binding cassette (ABC) transporters 
Another method to target LSC is to circumvent the 
problem of conventional chemotherapeutic drug 
resistance, due to high expression levels of 
ATP-dependent drug transporters in AML LSCs.156 The 
ABC transporter family comprises 49 functionally 
distinct transmembrane proteins, classified as 7 
subfamilies (ABCA through ABCG).156 The first and 
second generations of MDR1 inhibitors, such as 
verapamil and PSC-833 (valspodar) failed to achieve 
promising results.157-159 This may be due to multiple ABC 
transporters other than MDR1 itself being involved in 
drug efflux. Some studies demonstrated that the ABCG2 
transporter was predominant in HSCs instead of 
MDR1.160 Apparently, only modulating MDR1 is not 
enough in AML treatment. The third generation of MDR 
modulators with multiple functions are under 
development and evaluation.156 It should be noted that 
redundancy of ABC transporter expression not only exists 
in normal or leukemic stem cells, but also has relevant 
functions in liver and kidney, which dictate therefore the 
pharmacokinetics of the drug and increased toxicity.161 
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Other new agents 
Anti-angiogenesis agents are potential approaches in 
AML based on evidences that bone marrow biopsies from 
AML patients demonstrate increased neovascularization, 
which was associated with poor prognosis.162 Elevated 
level of vascular endothelial growth factor (VEGF) was 
identified in AML to promote disease progression.163 
SU5416 showed clinical activity in a phase II trial of 
AML patients who did not tolerate chemotherapy.104 
Other agents including thalidomide, a putative inhibitor 
of angiogenesis, and bevacizumab, an anti-VEGF 
antibody were also evaluated in clinical trials.164,165 So far 
no significant improvement in OS has been observed in 
elderly AML patients that have been treated 
chemotherapy alone. In the coming years the effects of 
lenalodomide in conjunction with chemotherapy will be 
tested. In patients with unfavorable-risk or refractory/ 
relapsed AML, second generation nucleoside analogues 
such as clofarabine and troxacitabine showed clinical 
activity by inhibiting DNA repair and activating apoptotic 
pathway.166,167 New agents targeting translation factors 




Clinical outcomes with standard therapies strongly 
depend on the risk group, especially the outcomes for 
elderly patients. Probably this is related to a difference in 
cell biology between the older and younger leukemic 
stem cells. A recent microarray study in younger and 
elderly AML patients demonstrated that p16INK4A 
expression was down-regulated with increasing age in the 
intermediate and unfavorable risk group, which was in 
contrast to the elevated expression level of p16INK4A 
with physiologic aging.170 It is likely that new insights 
into the multiple transforming events of AML will lead to 
a better definition of the therapeutic targets. Ultimately by 
combining small molecule inhibitors that specifically 
target the genotype-specific mutations we should be able 
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